TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01680900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo capsules matched to drug capsules.
Study: NCT04695964

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICG-NIRF Imaging plus ingress and egress analysis
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
Study: NCT04545346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glutamate diet
Description: Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
Study: NCT00898560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate and Microginon®
Description: eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period

Intervention type: DRUG
Group type: OTHER
Intervention: Microginon®
Description: Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
Study: NCT01677715

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Mei Yi Tian active lactobacillus drink
Description: 100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: recombined milk drink contains no lactobacillus
Description: 100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
Study: NCT03887754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
Study: NCT00999037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: Daily renvela (800 mg tid with meals) x 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 inert tablet tid x 12 weeks
Study: NCT03887754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non specific Multivitamin
Description: control group received non specific multivitamins as placebo for 8 months.
Study: NCT03413150

Intervention type: DRUG
Intervention: Amiodarone
Description: Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
Study: NCT01490619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Thinking In Teens
Description: 9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Diabetes Education.
Description: 9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
Study: NCT00865020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Telmisartan
Description: Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
Study: NCT00782366

Intervention type: GENETIC
Intervention: SNP analysis
Description: The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
Study: NCT02154412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Training
Description: Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
Study: NCT00996099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment
Description: Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive insulin therapy using standard protocol
Description: Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
Study: NCT01582308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study: NCT00105196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole+ ADT
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Study: NCT03373604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK-6240
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study: NCT00726687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: indibulin, dose escalation, 400-600 mg taken twice every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
Study: NCT01382693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TimeSlips
Description: TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care activity program
Description: Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
Study: NCT04686630

Intervention type: OTHER
Intervention: Video based observational gait analysis and SCALE Test
Description: Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
Study: NCT02490293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporin
Description: During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.
Study: NCT02705989

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986195
Description: Specified dose on specified day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986195
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Specified dose on specified day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986195
Description: Specified dose on specified day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day
Study: NCT05628220

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: rehabilitation through using session of virtual reality desensitization
Study: NCT01964352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination
Study: NCT00105196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ ADT
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Study: NCT03340727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
Study: NCT01921920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
Study: NCT01850056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon catheter (trade name: Orchid)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)
Study: NCT00166205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swedish Adjustable Gastric Band
Description: Long term implantable device.
Study: NCT03314545

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laminate veneer with coronal post
Description: laminate veneer with coronal post

Intervention type: PROCEDURE
Group type: OTHER
Intervention: post,core and crown
Description: post,core and crown
Study: NCT03772626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-flow Nasal Cannula
Description: Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
Study: NCT01823679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally
Study: NCT03842826

Intervention type: DIAGNOSTIC_TEST
Intervention: Palpation, resistance and stretch tests
Description: Palpation, resistance and stretch tests performed by 2 blinded examiners.
Study: NCT02164981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitroprusside
Description: intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: sodium nitroprusside
Description: intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00465959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride inhalation powder (TrIP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride inhalation powder (TrIP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00809770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non Contingent Control Condition
Description: Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
Study: NCT00144898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Resection
Description: Sentinel Node Resection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Axillary Dissection
Description: Conventional Axillary Dissection
Study: NCT01039337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip School
Description: The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip School and Manual Treatment
Description: Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal control intervention
Description: As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
Study: NCT01526512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metroCX
Description: cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
Study: NCT04711772

Intervention type: OTHER
Intervention: whole-genome sequencing
Description: Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.

Intervention type: OTHER
Intervention: whole-genome sequencing
Description: Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
Study: NCT03536455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01972230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan + Remifentanil TCI
Study: NCT02969057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with rice bran oil gel
Description: 25 grams of rice bran oil gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with rice bran oil
Description: 25 grams of rice bran oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with palm oil gel
Description: 25 grams of palm oil gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with palm oil
Description: 25 grams of palm oil
Study: NCT04349423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Usage Manipulation
Description: Behavioral Intervention of social media usage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Usage Manipulation
Description: Behavioral Intervention of social media usage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Usage Manipulation
Description: Behavioral Intervention of social media usage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Usage Manipulation
Description: Behavioral Intervention of social media usage.